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ABSTRACT
Objective To evaluate the efﬁcacy and safety of
etanercept (ETN) after 48 weeks in patients with early
active non-radiographic axial spondyloarthritis
(nr-axSpA).
Methods Patients meeting Assessment of
SpondyloArthritis international Society (ASAS)
classiﬁcation criteria for axSpA, but not modiﬁed
New York radiographic criteria, received double-blind
ETN 50 mg/week or placebo (PBO) for 12 weeks, then
open-label ETN (ETN/ETN or PBO/ETN). Clinical, health,
productivity, MRI and safety outcomes were assessed
and the 48-week data are presented here.
Results 208/225 patients (92%) entered the open-
label phase at week 12 (ETN, n=102; PBO, n=106). The
percentage of patients achieving ASAS40 increased from
33% to 52% between weeks 12 and 48 for ETN/ETN
and from 15% to 53% for PBO/ETN (within-group p
value <0.001 for both). For ETN/ETN and PBO/ETN, the
EuroQol 5 Dimensions utility score improved by 0.14 and
0.08, respectively, between baseline and week 12 and
by 0.23 and 0.22 between baseline and week 48.
Between weeks 12 and 48, MRI Spondyloarthritis
Research Consortium of Canada sacroiliac joint (SIJ)
scores decreased by −1.1 for ETN/ETN and by −3.0 for
PBO/ETN, p<0.001 for both. Decreases in MRI SIJ
inﬂammation and C-reactive protein correlated with
several clinical outcomes at weeks 12 and 48.
Conclusions Patients with early active nr-axSpA
demonstrated improvement from week 12 in clinical,
health, productivity and MRI outcomes that was
sustained to 48 weeks.
Trial registration number NCT01258738.
INTRODUCTION
MRI to detect inﬂammation before the develop-
ment of X-ray changes is an important tool for
diagnosing spondyloarthritis (SpA).1–5 The
Assessment of SpondyloArthritis international
Society (ASAS) have created a classiﬁcation system
for axial SpA (axSpA) based on whether patients
meet clinical criteria or imaging criteria.6 7 Patients
meeting ASAS criteria for axSpA without sacroiliitis
on X-ray examination are classiﬁed as having non-
radiographic axSpA (nr-axSpA). In several recent
studies, anti-tumour necrosis factor agents, includ-
ing etanercept (ETN), demonstrated efﬁcacy in
patients with nr-axSpA.8–15 However, additional
long-term data are needed.
In the ﬁrst period of an ongoing, randomised,
placebo-controlled study (ClinicalTrials.gov identi-
ﬁer: NCT01258738), patients with early nr-axSpA
unresponsive to two or more non-steroidal anti-
inﬂammatory drugs (NSAIDs) experienced signiﬁ-
cant improvement in clinical signs and symptoms
and MRI-measured inﬂammation after 12 weeks of
double-blind treatment with ETN; clinical improve-
ment continued for the next 12 weeks of the open-
label period.14 This report provides clinical, health,
productivity, MRI and safety data to week 48 and
evaluates whether (1) treatment response improves
between 12 and 24 weeks; (2) treatment response
is sustained over 48 weeks; (3) decreases in MRI
scores continue between weeks 12 and 48; (4) a




Details of the study design were published previ-
ously.14 Patients were aged 18–49 years; met ASAS
axSpA criteria; had symptom duration >3 months
and <5 years and a Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) score >4; and
treatment with two or more NSAIDs had failed.
Patients were excluded if they met the modiﬁed
New York criteria for radiographic axSpA con-
ﬁrmed by central reading.16 MRI was obtained
during screening to look for sacroiliac joint (SIJ)
inﬂammation; all patients met the ASAS imaging
criteria (sacroiliitis on imaging and one or more
SpA features) or clinical criteria (human leucocyte
antigen (HLA)-B27 positive and two or more other
SpA features). Patients were stratiﬁed by positive or
negative sacroiliitis and geographical region.
Study design
This ongoing phase IIIb, 104-week clinical study
consists of a 12-week randomised, double-blind
period in which patients received 50 mg ETN sub-
cutaneously once a week or placebo (PBO), then a
92-week open-label phase in which all patients
received 50 mg ETN weekly. All patients continued
background NSAID treatment. Clinical assessments
at weeks 2, 4, 8, 12, 16, 24, 32, 40 and 48
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included: ASAS20, ASAS40,17 ASAS5/6, ASAS partial remission,
BASDAI50 and Ankylosing Spondylitis Disease Activity Score
inactive disease (ASDAS<1.3).7 Assessments were added for
continuous ASDAS based on C-reactive protein (CRP), BASDAI,
Bath Ankylosing Spondylitis Functional Index (BASFI), Bath
Ankylosing Spondylitis Metrology Index (BASMI) and total
back pain.7 CRP measurements were performed centrally using
a high-sensitivity assay. Patients were also assessed using MRI of
the SIJ and spine. Scoring methods included Spondyloarthritis
Research Consortium of Canada (SPARCC)18 19 SIJ and spine
6-discovertebral units; and Ankylosing Spondylitis spine
MRI-activity (ASspiMRI-a)20 at baseline, weeks 12 and 48.
Additionally, patient-reported health-related quality-of-life
assessments were administered, including the EuroQol 5
Dimensions (EQ-5D)21 and the 36-item Short Form Health
Survey (SF-36) physical and mental components.22 SF-36 was
assessed at baseline and weeks 4, 12, 24 and 48; EQ-5D addi-
tionally at weeks 8, 16 and 40.
The Work Productivity and Activity Impairment (WPAI) ques-
tionnaire was also collected.23 This questionnaire concerns the
effect of the speciﬁed health problem on work absence and
productivity and regular activities. It includes several subscale
scores; overall work impairment is presented. Scores range from
0 to 100; higher numbers indicate greater impairment and less
productivity. WPAI was collected at weeks 2, 4, 8, 12, 16, 24,
32, 40 and 48.
MRI
All study MRIs were performed locally, collected and then read
centrally. The ﬁrst MRI was performed during screening, after
the SIJ X-ray report from the central reader had been reviewed
by the investigator. The X-ray result was required to be negative
for radiological sacroiliitis grades 3–4 unilaterally or grade ≥2
bilaterally, deﬁned by the modiﬁed New York criteria for radio-
graphic axSpA. The screening MRI was assessed by a central
reader to determine whether it was positive for sacroiliitis
according to ASAS criteria. This MRI was also included with
MRI scans obtained at 12 and 48 weeks in reading exercises by
central readers who scored the scans for the degree of SIJ and
spinal inﬂammation.
Two independent readers scored the screening, 12- and
48-week MRI scans, which were assessed simultaneously,
blinded to time point, treatment and patient characteristics. A
third reader assessed MRI scans with discrepant scores accord-
ing to prespeciﬁed adjudication rules. Results requiring adjudica-
tion were identiﬁed after the two independent reviews were
completed. Adjudication was required for those cases in which
one reader considered the MRI results to be unreadable, or if
the scores moved in different directions (one positive, one nega-
tive) and differed by >5 points for ASspiMRI-a or SPARCC
spinal and by >3 points for SPARCC SIJ.
In a post hoc completer analysis, structural lesions at baseline
and week 48 were scored using the SPARCC MRI SIJ structural
score (SSS), assessing fat metaplasia, erosion, backﬁll and anky-
losis on T1-weighted spin echo MRI and assigning a yes/no
score according to the presence/absence of lesions in SIJ quad-
rants (fat metaplasia, erosion) or SIJ halves (backﬁll, anky-
losis).24 Five consecutive semicoronal slices were assessed by
scrolling anteriorly from the transitional slice, the ﬁrst cartil-
aginous slice that visualises the ligamentous joint when viewed
anteriorly to posteriorly. Fat and erosion were each assigned a
0–8 score per slice for ﬁve slices, for a scoring range of 0–40.
Backﬁll and ankylosis were each assigned a 0–4 score per slice
for ﬁve slices, for a scoring range of 0–20.
Statistical methods
Analyses of clinical and imaging efﬁcacy used the open-label
modiﬁed intention-to-treat (mITT) population, consisting of all
patients in the double-blind mITT population who took one or
more doses of the study drug and had one or more visits during
the open-label period. Clinical efﬁcacy and MRI analyses used
the mITT, last observation carried forward population, and the
health and productivity outcomes analyses used the mITT,
observed case (OC) population. Between-group p values at
12 weeks for clinical, health and productivity outcomes were
determined using analysis of covariance models. Paired t tests
were used to compare within-group differences between base-
line and 48 weeks and other time points for the clinical, health
outcomes and MRI scores. Within-group differences between
weeks 12 and 48 and weeks 24 and 48 for the ETN/ETN
group, OC population, were examined using paired t tests for
ASDAS, BASDAI, BASMI, BASFI, CRP and total back pain post
hoc and were determined using McNemar’s test for ASAS20,
ASAS40, ASAS 5/6, ASAS partial remission, ASDAS inactive
disease and BASDAI50 post hoc. Two 48-week efﬁcacy end-
points were added that were not in the study protocol: ASDAS
clinically important improvement and ASDAS major
improvement.25
Spearman correlations (R) were used to evaluate the correl-
ation between change from baseline for SPARCC MRI SIJ score
as well as CRP and change from baseline for ASDAS, BASDAI,
BASMI, BASFI and total back pain (OC population) and fat
metaplasia, erosion, backﬁll and ankylosis (48-week completers),
post hoc.
The open-label safety population included all patients who
completed the double-blind period and took one or more doses
of the study drug during the open-label period.
RESULTS
Patients
Of the 215 patients comprising the double-blind mITT popula-
tion, 208 patients entered the open-label period (ETN/ETN,
n=102; PBO/ETN, n=106) and 190 patients completed
48 weeks (ETN/ETN, n=92; PBO/ETN, n=98; ﬁgure 1). The
mITT population for the open-label period included 205
patients (ETN/ETN, n=100; PBO/ETN, n=105). For the open-
label safety population, baseline mean (SD) age was 32 (7.8)
years, 61% were male, 74% were white and mean duration of
disease symptoms was 2.5 (1.9) years (table 1). Mean CRP was
6.7 (10.7) and 148/208 (71.2%) patients were HLA-B27 posi-
tive. BASDAI was 6.0 (1.8), indicating that patients had moder-
ate to severe disease. Most patients (169/208, 81%) met ASAS
imaging criteria; 39/208 (19%) patients did not meet imaging
criteria but met ASAS clinical criteria and 54% of patients met
both.6
Clinical efﬁcacy
By week 48, 108/205 (53%) patients achieved ASAS40, 52%
and 53% in the ETN/ETN and PBO/ETN groups, respectively
(ﬁgure 2A). Between weeks 12 and 48, the percentage of
patients achieving ASAS20, ASAS 5/6, ASDAS inactive disease
and BASDAI50 increased for the two treatment groups and
both groups achieved similar results at week 48 (ﬁgures 2B–F).
Improvement in ASDAS and BASDAI continued between weeks
12 and 48 for both groups (table 2). Mean (SD) values are pro-
vided in online supplementary table S1. At 48 weeks, ASDAS
clinically important improvement was achieved by 64/100
(64%) and 68/105 (65%) patients receiving ETN/ETN and
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PBO/ETN, respectively; ASDAS major improvement was
achieved by 37/100 (37%) and 35/105 (33%) patients. For
ETN/ETN, function, measured by BASFI, improved signiﬁcantly
between weeks 12 and 48, p<0.001; change in mobility
measured by BASMI was not statistically signiﬁcant (table 2).
CRP decreased between weeks 12 and 48, from a mean (SEM)
of 3.0 (0.6) to 2.2 (0.5) for ETN/ETN, p=NS; and from 6.0
(1.0) to 1.7 (0.2) for PBO/ETN, p<0.001.
In a post hoc analysis, within-group improvement between
weeks 12 and 48 for ETN/ETN was signiﬁcant for ASDAS,
BASDAI and BASFI (p<0.001 for all) and total back pain
(p<0.01); BASMI was not signiﬁcant (table 2). Between weeks
24 and 48, within-group improvement was signiﬁcant at
p<0.01 for BASFI, p<0.05 for ASDAS, BASDAI and total back
pain; BASMI was not signiﬁcant.
For the ETN/ETN group, a signiﬁcantly greater proportion of
patients at 48 weeks than 12 weeks achieved ASAS40 and ASAS
5/6 (p<0.001), ASAS20 and BASDAI50 (p<0.01) and ASAS
partial remission (p<0.05); ASDAS inactive disease was not sig-
niﬁcant (ﬁgure 2A–F). Between weeks 24 and 48, within-group
improvement was signiﬁcant only for BASDAI50 (p<0.05).
Thus, for efﬁcacy outcomes, the greatest clinical improvement
for ETN/ETN was between weeks 12 and 24.
Patient-reported outcomes
Between baseline and 12 weeks, there was signiﬁcantly greater
improvement with ETN than PBO in the SF-36 physical compo-
nent score (PCS), p<0.05; differences in the EQ-5D utility score,
SF-36 mental component score (MCS) and WPAI overall were
not statistically signiﬁcant (table 2). Between weeks 12 and 48,
Table 1 Baseline demographics and disease characteristics of patients entering the open-label period
ETN/ETN (n=102) PBO/ETN (n=106) Combined (n=208)
Age, years 31.6 (7.8) 32.1 (7.7) 31.9 (7.8)
Male, n (%) 65 (63.7) 61 (57.5) 126 (60.6)
White, n (%) 77 (75.5) 77 (72.6) 154 (74.0)
BMI, kg/m2 25.6 (5.0) 24.6 (4.1) 25.1 (4.6)
Duration of disease symptoms, years 2.4 (2.0) 2.5 (1.8) 2.5 (1.9)
HLA-B27 positive, n (%) 68 (66.7) 80 (75.5) 148 (71.2)
CRP, mg/L 7.0 (10.7) 6.4 (10.6) 6.7 (10.7)
Elevated CRP (>3 mg/L), n (%) 48 (47.1) 42 (39.6) 90 (43.3)
BASDAI, 0–10 cm VAS 6.0 (1.8) 6.0 (1.9) 6.0 (1.8)
BASFI, 0–10 cm VAS 4.2 (2.4) 3.8 (2.5) 4.0 (2.4)
BASMI, 0–10 cm VAS 1.4 (1.3) 1.2 (1.3) 1.3 (1.3)
Total back pain, 0–10 cm VAS 5.5 (2.4) 5.4 (2.4) 5.5 (2.4)
PGA, 0–10 cm VAS 5.7 (1.8) 5.2 (1.9) 5.4 (1.9)
PtGA, 0–10 cm VAS 5.8 (2.2) 5.8 (2.1) 5.8 (2.2)
ASDAS-CRP 3.0 (0.9) 3.0 (1.0) 3.0 (1.0)
EQ-5D utility score, range 0–1 0.52 (0.33) 0.59 (0.28) 0.56 (0.31)
SF-36 MCS, range 0–100 42.3 (11.9) 43.5 (11.1) 42.9 (11.5)
SF-36 PCS, range 0–100 37.7 (8.6) 37.4 (8.3) 37.5 (8.4)
WPAI overall, range 0–100* 45.0 (26.2) 43.9 (27.8) 44.5 (26.9)
MRI sacroiliitis positive by ASAS criteria, n (%) 84 (82.4) 85 (80.2) 169 (81.3)
SPARCC MRI SIJ score, range 0–72 7.9 (10.9) 7.0 (11.0) 7.4 (10.9)
SPARCC MRI 6-DVU spinal score, range 0–108 7.6 (11.4) 6.9 (9.2) 7.2 (10.3)
ASspiMRI-a score, range 0–138 1.6 (2.5) 1.4 (1.7) 1.5 (2.1)
*ETN/ETN, n=58; PBO/ETN, n=58.
Open-label safety population, except BASMI, SF-36 MCS, WPAI overall, SPARCC MRI SIJ, SPARCC MRI spinal, ASspiMRI-a, which are mITT from the double-blind period (ETN/ETN,
n=106; PBO/ETN, n=109).
Values are shown as mean (SD) unless stated otherwise.
ASAS, Assessment of SpondyloArthritis international Society; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score based on C-reactive protein; ASspiMRI-a, Ankylosing Spondylitis
spine MRI-activity; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index;
BMI, body mass index; CRP, C-reactive protein; DVU, discovertebral units; EQ-5D, EuroQol 5 Dimensions; ETN, etanercept; HLA-B27, human leucocyte antigen B27; MCS, mental
component summary; mITT, modified intention-to-treat; PBO, placebo; PCS, physical component summary; PGA, physician global assessment; PtGA, patient global assessment; SF-36,
36-item Short Form Health Survey; SIJ, sacroiliac joint; SPARCC, Spondyloarthritis Research Consortium of Canada; VAS, visual analogue scale; WPAI, Work Productivity and Activity
Impairment questionnaire.
Figure 1 Patient disposition, full analysis population. AE, adverse
event; ETN, etanercept; PBO, placebo; QW, once weekly.
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Figure 2 Proportion of patients achieving (A) ASAS40 response, (B) ASAS20 response, (C) ASAS partial remission, (D) ASAS 5/6, (E) ASDAS
inactive disease and (F) BASDAI50. Population is modiﬁed intention-to-treat (mITT), last observation carried forward (LOCF). The actual number of
patients, observed case (OC), is also shown. p Values for differences in results between weeks 12 and 48 and between weeks 24 and week 48 for
the ETN/ETN group are from McNemar’s test, OC data. ASAS, Assessment of SpondyloArthritis international Society; ASDAS, Ankylosing Spondylitis
Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ETN, etanercept; ns, non-signiﬁcant; PBO, placebo; Δ, change.
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the EQ-5D utility score, SF-36 PCS and MCS and WPAI overall
continued to improve for both treatment groups (table 2).
Within-group response difference for ETN/ETN between
weeks 12 and 48 was signiﬁcant at p<0.05 for SF-36 PCS and
WPAI overall; SF-36 MCS and EQ-5D utility score were not sig-
niﬁcant (table 2). Between weeks 24 and 48, within-group
response difference was not signiﬁcant for any patient-reported
outcomes. Overall, for patient-reported outcomes, improvement
continued between weeks 12 and 48, but was not statistically
signiﬁcant between weeks 24 and 48.
MRI results
Between baseline and 12 weeks, the decrease in MRI scores dif-
fered signiﬁcantly between ETN and PBO.14 SPARCC SIJ and
spinal MRI scores continued improving to week 48 for the
ETN/ETN and PBO/ETN groups (ﬁgure 3A, B). Mean (SD)
changes in SPARCC SIJ MRI scores between baseline and week
48 were −5.8 (10.3) and −4.1 (8.3) for ETN/ETN and PBO/
ETN, respectively and were −1.1 (2.9) and −3.0 (7.5) between
weeks 12 and 48. Mean (SD) changes in SPARCC spinal MRI
scores were −4.8 (11.3) and −4.2 (7.6) for ETN/ETN and PBO/
ETN, respectively, between baseline and week 48. The
within-group p value for change from baseline to week 48 and
week 12 to week 48 was <0.001 for all.
Mean (SD) changes in ASspiMRI-a scores were −0.68 (2.25)
and −0.52 (1.38) for ETN/ETN and PBO/ETN, respectively,
between baseline and week 48 (ﬁgure 3C). Within-group p
values for change were <0.01 for ETN/ETN and <0.001 for
PBO/ETN between baseline and 48 weeks; change between
weeks 12 and 48 was non-signiﬁcant for ETN/ETN and was sig-
niﬁcant for PBO/ETN (p<0.001). Online supplementary ﬁgure
S1 provides mean SPARCC SIJ and spinal MRI scores and
ASspiMRI-a scores.
Between baseline and 48 weeks, SSS scores for fat metaplasia,
backﬁll and ankylosis increased by a mean (95% CI) of 0.46
(0.15 to 0.77), 0.89 (0.59 to 1.19) and 0.04 (0 to 0.09),
respectively and erosion score decreased by −1.29 (−1.65 to
−0.92) for the combined ETN/ETN and PBO/ETN group (see
online supplementary ﬁgure S2).
Analysis of correlation between MRI and clinical outcomes
Decreases in SPARCC SIJ score from baseline correlated with
changes in several clinical measurements and structural lesions
in the ETN/ETN group (table 3). At week 12, the score decrease
correlated weakly with improvement in ASDAS, BASDAI, total
back pain, CRP and ASAS40 (R ranged from 0.27 to 0.35). By
week 48, correlations with improvement in ASDAS, BASDAI
and total back pain were moderate (R ranged from 0.42 to
0.58, p<0.001) and a weak correlation with BASFI emerged.
From baseline to week 48, reduction in SPARCC SIJ inﬂamma-
tion score correlated signiﬁcantly with development of new fat
metaplasia and backﬁll (R=−0.28, p<0.01 and R=−0.61,
Table 2 Mean (SEM) change from baseline for clinical efficacy and patient-reported outcomes
Double-blind phase Open-label phase p Values†
Week 12
Week 12





N=Pts in study ETN/ETN N=101 N=99 N=98 N=94 N=93 N=91
PBO/ETN N=106 N=104 N=103 N=100 N=99 N=99
ASDAS-CRP ETN/ETN −1.1 (0.1) <0.001 −1.4 (0.1) −1.5 (0.1) −1.4 (0.1) −1.6 (0.1) −1.6 (0.1) <0.001 <0.05
PBO/ETN −0.5 (0.1) −1.4 (0.1) −1.6 (0.1) −1.5 (0.1) −1.6 (0.1) −1.6 (0.1)
BASDAI ETN/ETN −2.0 (0.3) <0.05 −2.7 (0.2) −2.9 (0.2) −2.7 (0.2) −3.2 (0.2) −3.2 (0.2) <0.001 <0.05
PBO/ETN −1.3 (0.3) −3.0 (0.2) −3.3 (0.2) −3.2 (0.2) −3.4 (0.2) −3.5 (0.2)
BASFI ETN/ETN −1.4 (0.2) <0.05 −1.8 (0.2) −1.9 (0.2) −1.8 (0.2) −2.2 (0.2) −2.2 (0.2) <0.001 <0.01
PBO/ETN −0.8 (0.2) −1.8 (0.2) −1.9 (0.2) −2.0 (0.2) −2.1 (0.2) −2.1 (0.2)
BASMI ETN/ETN −0.3 (0.2) NS −0.4 (0.1) −0.5 (0.1) −0.6 (0.1) −0.5 (0.1) −0.5 (0.1) NS NS
PBO/ETN −0.3 (0.1) −0.4 (0.1) −0.3 (0.1) −0.5 (0.1) −0.5 (0.1) −0.4 (0.1)
Total back pain ETN/ETN −2.0 (0.3) <0.01 −2.7 (0.3) −2.8 (0.3) −2.6 (0.3) −3.3 (0.3) −3.1 (0.3) <0.01 <0.05
PBO/ETN −1.1 (0.3) −2.6 (0.3) −2.9 (0.2) −2.9 (0.3) −3.2 (0.2) −3.2 (0.3)
SF-36 PCS ETN/ETN 6.2 (1.0) <0.05 NA 6.7 (0.9) NA NA 8.0 (1.0) <0.05 NS
PBO/ETN 3.8 (0.9) NA 7.3 (0.8) NA NA 8.5 (0.9)
SF-36 MCS ETN/ETN 2.4 (1.3) NS NA 3.5 (1.3) NA NA 3.5 (1.2) NS NS
PBO/ETN 1.6 (1.2) NA 4.4 (1.0) NA NA 3.5 (1.1)
EQ-5D utility
score
ETN/ETN 0.14 (0.04) NS 0.19 (0.04) 0.21 (0.03) NA 0.24 (0.04) 0.23 (0.03) NS NS
PBO/ETN 0.08 (0.03) 0.17 (0.03) 0.20 (0.03) NA 0.18 (0.03) 0.22 (0.03)
N=Pts with
work data
ETN/ETN N=48 N=49 N=45 N=46 N=45 N=45
PBO/ETN N=50 N=46 N=43 N=43 N=47 N=45
WPAI overall ETN/ETN −20.8 (4.9) NS −16.3 (3.8) −14.9 (4.5) −17.6 (3.8) −23.7 (4.2) −23.0 (3.6) <0.05 NS
PBO/ETN −12.1 (4.9) −16.4 (2.9) −18.6 (3.7) −16.5 (3.3) −20.5 (3.0) −17.5 (3.9)
*Analysis of covariance model used for between-group p values.
†Paired t test used for within-group response difference for ETN/ETN.
Analyses performed on mITT, LOCF population for ASDAS-CRP, BASDAI, BASFI, BASMI, total back pain; mITT, observed case population for SF-36 PCS, SF-36 MCS, EQ-5D utility score,
WPAI overall.
ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score based on C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis
Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; EQ-5D, EuroQol 5 Dimensions; ETN, etanercept; LOCF, last observation carried forward; MCS, mental component
summary; mITT, modified intention-to-treat; NA, not available, NS, non-significant; PCS, physical component summary; PBO, placebo; Pts, patients; SEM, SE of the mean; SF-36, 36-item
Short Form Health Survey; WPAI, Work Productivity and Activity Impairment questionnaire.
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p<0.001, respectively). Reduction in SPARCC SIJ inﬂammation
score also correlated signiﬁcantly with reduction in erosion
score (R=0.57, p<0.001).
For PBO/ETN, there was only a weak correlation between
reduction in SPARCC SIJ inﬂammation and improvement in
CRP (R=0.22) at 12 weeks, but upon switching to open-label
ETN, signiﬁcant correlations with ASDAS and CRP (R=0.24,
p<0.05 and R=0.32, p<0.01) emerged at 48 weeks. The
decrease in SPARCC SIJ inﬂammation score from baseline to
week 48 correlated signiﬁcantly with development of new fat
metaplasia and backﬁll (R=−0.46, p<0.001 and R=−0.43,
p<0.001) and with reduction in erosion score (R=0.55,
p<0.001). There was no pattern of correlation between clinical
outcomes and SPARCC spinal MRI score (see online
supplementary table S2).
A decrease from baseline in CRP correlated with clinical
changes in the ETN/ETN group (table 3). At week 12, CRP
change correlated strongly with ASDAS improvement (R=0.61)
and weakly with BASDAI, BASMI, BASFI and total back pain
improvement (R ranged from 0.20 to 0.34). At week 48, these
clinical correlations were preserved at approximately the
12-week levels and lower CRP correlated with a decrease in
erosion score (R=0.25, p<0.05). For PBO/ETN, there was only
a weak correlation (R=0.37) with improved ASDAS at
12 weeks, but after switching to open-label ETN, additional sig-
niﬁcant clinical correlations emerged at 48 weeks. There were
no signiﬁcant correlations with structural lesion changes.
Safety
Between weeks 12 and 48, 133/208 (64%) patients had an
adverse event (AE) owing to treatment. The most common AEs
(occurring in >5% of patients) were nasopharyngitis (15%) and
upper respiratory tract infection (6%). Investigator-identiﬁed
infections were reported in 21% of patients; none of the infec-
tions were serious. Four patients (2%) experienced serious AEs;
one serious AE (fever) was considered to be related to the study
drug. Two patients discontinued the study owing to the
treatment-emergent AEs of bronchitis and fever. There were no
reports of demyelinating disorder, active tuberculosis, malignan-
cies or deaths. One case of herpes zoster was seen, which was not
considered serious; ETN was discontinued and the AE resolved.
Figure 3 Mean change from baseline for (A) SPARCC MRI SIJ score, (B) SPARCC MRI spinal score and (C) ASspiMRI-a total score. Population is
mITT, LOCF within each study period. The actual number of patients, observed case (OC), is also shown. Mean (SD) baseline values: (A) 7.9 (10.9)
for ETN/ETN and 7.0 (11.0) for PBO/ETN; (B) 7.6 (11.4) for ETN/ETN and 6.9 (9.2) for PBO/ETN; (C) 1.6 (2.5) for ETN/ETN and 1.4 (1.7) for PBO/ETN.
Changes in score between weeks 12 and 48: (A) −1.1 (2.9) for ETN/ETN and −3.0 (7.5) for PBO/ETN; (B) −1.9 (4.7) for ETN/ETN and −3.6 (5.9) for
PBO/ETN; (C) −0.06 (0.68) for ETN/ETN and −0.46 (1.15) for PBO/ETN. Within-group p value between baseline and week 48 from paired t test:
<0.001 for all, except ASspiMRI-a total score for ETN/ETN: p<0.01. Within-group p value between week 12 and week 48 from paired t test: <0.001
for all, except ASspiMRI-a total score for ETN/ETN which was non-signiﬁcant. ASspiMRI-a, Ankylosing Spondylitis spine MRI-activity; ETN,
etanercept; LOCF, last observation carried forward; mITT, modiﬁed intention-to-treat; PBO, placebo; SIJ, sacroiliac joint; SPARCC, Spondylitis Research
Consortium of Canada.
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DISCUSSION
Limited data are available on the 48-week efﬁcacy, safety, MRI,
health and productivity outcomes of using tumour necrosis factor
inhibitors in nr-axSpA. In this analysis, clinical efﬁcacy, patient-
reported health-related quality-of-life, productivity and MRI out-
comes improved between weeks 12 and 48 with ETN treatment;
improvement of clinical and health outcomes was greater between
weeks 12 and 24 than between weeks 24 and 48. After week 24
there was not an increase in the number of patients who
responded, but those who did showed a greater response. This
improvement is probably genuine, since there were few dropouts
and clinical results correlated weakly by week 12 and then moder-
ately by week 48 with objective improvement in SIJ MRI scores.
We compared 12- and 48-week clinical and SIJ MRI
responses and observed signiﬁcant improvement and correlation
in certain outcomes. Although the natural history of axSpA and
its relationship to SIJ inﬂammation is incompletely understood,
these data suggest that ETN may mediate back pain relief and
improve clinical indices in axSpA by decreasing inﬂammation in
the SIJ, the site of disease symptoms.
In contrast to the clinical correlation with SIJ MRI, there was
minimal correlation with spinal MRI SPARCC score changes,
probably owing to the low level of spinal inﬂammation in
patients with disease duration of <5 years. Notably, there was no
signiﬁcant spinal MRI improvement between weeks 12 and 48
using ASspiMRI-a scoring. The lack of consistent decreases in
spinal MRI inﬂammation may be due to scoring differences
between SPARCC and ASspiMRI-a, or a low spinal disease
burden in this population with a short symptom duration.
Previous analyses of a correlation between MRI and clinical
outcomes in patients with nr-axSpA yielded mixed results.10 15
There are several possible explanations for the discrepancy
between previously published results and those presented here.
Patients in this study had a relatively short symptom duration
(<5 years) and not all patients in the other studies met ASAS
criteria for nr-axSpA. Patients were chosen and images were
interpreted by a central reader, thereby decreasing entry bias
and minimising the possibility of admitting patients with radio-
graphic evidence of AS.
One study limitation was an open-label design beyond
12 weeks and unblinding to the study drug. However, the low
dropout rate and continued improvement in MRI reduce the
likelihood that the clinical outcomes to 48 weeks resulted from
a placebo effect. Additionally, efﬁcacy results during the
48 weeks were imputed using the last observation carried
forward and therefore do not represent the actual number of
patients in the study at each time point. As expected, the OC
population was smaller (ﬁgures 2 and 3), but the difference is
slight, owing to the low dropout rate. As reported previously,
clinical improvement occurred between 12 and 24 weeks, but
no MRI was performed at week 24. Therefore, we cannot pin-
point precisely the timing of the correlation of clinical and MRI
improvement seen between weeks 12 and 48 and it is possible
that imaging improvement lagged behind clinical improvement.
Safety outcomes at 48 weeks were similar to those at 12 and
24 weeks and similar to those in the clinical trials that evaluated
ETN for ankylosing spondylitis.26–29
In summary, these results demonstrate the long-term efﬁcacy
of ETN in treating patients with early nr-axSpA unresponsive to
NSAIDs. Improvement in clinical, health, productivity and
imaging outcomes was sustained to 48 weeks. These results
were supported by correlations between decreased inﬂamma-
tion, as measured by MRI and CRP, and clinical outcomes.
There were no new safety signals.
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Table 3 Correlation between change from baseline in SPARCC SIJ
score or CRP and change in clinical and SPARCC SSS measures,
ETN/ETN group
Δ SPARCC SIJ Δ CRP
N R N R
ASDAS Week 12 Δ 94 0.35† 98 0.61†
Week 48 Δ 88 0.58† 89 0.58†
BASDAI Week 12 Δ 97 0.27* 100 0.22‡
Week 48 Δ 90 0.42† 90 0.30*
BASMI Week 12 Δ 94 0.07 97 0.34†
Week 48 Δ 88 0.14 88 0.28*
BASFI Week 12 Δ 97 0.17 100 0.20‡
Week 48 Δ 90 0.35† 90 0.20
Total back pain Week 12 Δ 97 0.28* 100 0.20‡
Week 48 Δ 90 0.45† 90 0.20
CRP Week 12 Δ 96 0.31*
Week 48 Δ 89 0.37†
ASAS40 Week 12 Δ 97 −0.30* 100 −0.19
Week 48 Δ 90 −0.39† 90 −0.16
SSS Fat metaplasia Week 48 Δ 88 −0.28* 87 −0.07
SSS Erosion Week 48 Δ 88 0.57† 87 0.25‡
SSS Ankylosis Week 48 Δ 88 0.11 87 −0.08
SSS Backfill Week 48 Δ 88 −0.61† 87 −0.20
*p<0.01, †p<0.001, ‡p<0.05.
Clinical measures used observed case population. SSS scores include baseline and week
48; no values from an early termination visit were included.
For change from baseline to week 12 in the PBO/ETN group, the significant correlations
were R=0.37 for CRP/ASDAS and R=0.22 for SPARCC SIJ/CRP. For change from baseline
to week 48 in the PBO/ETN group, the significant correlations were: R=0.24 for SPARCC
SIJ/ASDAS; R=0.32 for SPARCC SIJ/CRP; R=−0.46 for SPARCC SIJ/fat metaplasia;
R=0.55 for SPARCC SIJ/erosion; R=−0.43 for SPARCC SIJ/backfill; R=0.62 for CRP/
ASDAS; R=0.31 for CRP/BASDAI; and R=0.30 for CRP/BASFI.
ASAS40, Assessment of SpondyloArthritis international Society 40; ASDAS, Ankylosing
Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity
Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing
Spondylitis Metrology Index; CRP, C-reactive protein; ETN, etanercept; PBO, placebo; R,
Spearman correlation; SIJ, sacroiliac joint; SPARCC, Spondylitis Research Consortium of
Canada; SSS, SPARCC MRI SIJ structural score.
1334 Maksymowych WP, et al. Ann Rheum Dis 2016;75:1328–1335. doi:10.1136/annrheumdis-2015-207596
Clinical and epidemiological research
group.bmj.com on January 10, 2017 - Published by http://ard.bmj.com/Downloaded from 
Competing interests WPM has received consulting fees from AbbVie, Amgen,
Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Pﬁzer, Synarc and UCB and is the
chief medical ofﬁcer of CaRE Arthritis Ltd. MD has received consulting fees from
Pﬁzer, AbbVie, Celgene, Eli Lilly, Novartis, Roche and Sanoﬁ-Aventis. DvdH has
received consulting fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb,
Novartis, Novo Nordisk, Otsuka, Pﬁzer, Roche, Sanoﬁ-Aventis, Schering-Plough,
UCB and Vertex and is the director of Imaging Rheumatology BV. JS has received
consulting fees from Böhringer-Ingelheim, Janssen, Novartis, AbbVie, Merck, Pﬁzer
and UCB. JB has received consulting fees from AbbVie, Celltrion, MSD, Novartis,
Pﬁzer and UCB. GC has received consulting fees from AbbVie, Bristol-Myers Squibb,
Pﬁzer and Roche and research grants from Pﬁzer. FVdB has received consulting
and/or speaker fees from Abbvie, Celgene, Janssen, Merck, Novartis, Pﬁzer and
UCB. IL, JW, HJ, LM, RB, RP, BV, SK and JFB are employees of Pﬁzer.
Ethics approval The ﬁnal protocol, any protocol amendments and informed
consent form for this study were reviewed and approved for use by each study
centre by a duly constituted institutional review board or independent ethics
committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Bennett AN, McGonagle D, O’Connor P, et al. Severity of baseline magnetic
resonance imaging–evident sacroiliitis and HLA–B27 status in early inﬂammatory
back pain predict radiographically evident ankylosing spondylitis at eight years.
Arthritis Rheum 2008;58:3413–18.
2 Braun J, Bollow M, Eggens U, et al. Use of dynamic magnetic resonance imaging
with fast imaging in the detection of early and advanced sacroiliitis in
spondylarthropathy patients. Arthritis Rheum 1994;37:1039–45.
3 Heuft-Dorenbosch L, Landewé R, Weijers R, et al. Combining information obtained
from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in
patients with recent onset inﬂammatory back pain. Ann Rheum Dis 2006;65:804–8.
4 Oostveen J, Prevo R, den Boer J, et al. Early detection of sacroiliitis on magnetic
resonance imaging and subsequent development of sacroiliitis on plain radiography.
A prospective, longitudinal study. J Rheumatol 1999;26:1953–8.
5 van der Heijde D, Sieper J, Maksymowych WP, et al. Spinal inﬂammation in the
absence of sacroiliac joint inﬂammation on magnetic resonance imaging in patients
with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol
2014;66:667–73.
6 Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of
SpondyloArthritis international Society classiﬁcation criteria for axial spondyloarthritis
(part II): validation and ﬁnal selection. Ann Rheum Dis 2009;68:777–83.
7 Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis
international Society (ASAS) handbook: a guide to assess spondyloarthritis.
Ann Rheum Dis 2009;68(Suppl 2):ii1–44.
8 Callhoff J, Sieper J, Weiß A, et al. Efﬁcacy of TNFα blockers in patients with
ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Ann Rheum Dis 2015;74:1241–8.
9 Landewé R, Braun J, Deodhar A, et al. Efﬁcacy of certolizumab pegol on signs and
symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week
results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum
Dis 2014;73:39–47.
10 Sieper J, van der Heijde D, Dougados M, et al. Efﬁcacy and safety of adalimumab in
patients with non-radiographic axial spondyloarthritis: results of a randomised
placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72:815–22.
11 Song IH, Weiß A, Hermann KGA, et al. Similar response rates in patients with
ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of
treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis
2013;72:823–5.
12 Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efﬁcacy of inﬂiximab in
HLA-B27-positive patients with magnetic resonance imaging-determined early
sacroiliitis. Arthritis Rheum 2009;60:946–54.
13 Haibel H, Rudwaleit M, Listing J, et al. Efﬁcacy of adalimumab in the treatment of
axial spondylarthritis without radiographically deﬁned sacroiliitis: results of a
twelve-week randomized, double-blind, placebo-controlled trial followed by an
open-label extension up to week ﬁfty-two. Arthritis Rheum 2008;58:1981–91.
14 Dougados M, van der Heijde D, Sieper J, et al. Symptomatic efﬁcacy of etanercept
and its effects on objective signs of inﬂammation in early nonradiographic axial
spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis Rheumatol 2014;66:2091–102.
15 Moltó A, Paternotte S, Claudepierre P, et al. Effectiveness of tumor necrosis factor α
blockers in early axial spondyloarthritis: data from the DESIR cohort. Arthritis
Rheumatol 2014;66:1734–44.
16 van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for
ankylosing spondylitis. A proposal for modiﬁcation of the New York criteria. Arthritis
Rheum 1984;27:361–8.
17 European Medicines Agency, Committee for Medicinal Products for Human Use.
Guideline on clinical investigation of medicinal products for the treatment of
ankylosing spondylitis. 2009. http://www.ema.europa.eu/docs/en_GB/document_
library/Scientiﬁc_guideline/2009/09/WC500003424.pdf
18 Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis Research
Consortium of Canada magnetic resonance imaging index for assessment of
spinal inﬂammation in ankylosing spondylitis. Arthritis Rheum 2005;
53:502–9.
19 Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis Research
Consortium of Canada magnetic resonance imaging index for assessment of
sacroiliac joint inﬂammation in ankylosing spondylitis. Arthritis Rheum
2005;53:703–9.
20 Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations
of the spine in patients with ankylosing spondylitis, before and after successful
therapy with inﬂiximab: evaluation of a new scoring system. Arthritis Rheum
2003;48:1126–36.
21 Boonen A, van der Heijde D, Landewé R, et al. How do the EQ-5D, SF-6D and the
well-being rating scale compare in patients with ankylosing spondylitis? Ann Rheum
Dis 2007;66:771–7.
22 Salafﬁ F, Carotti M, Gasparini S, et al. The health-related quality of life in
rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a comparison
with a selected sample of healthy people. Health Qual Life Outcomes 2009;7:25.
23 Reilly MC, Gooch KL, Wong RL, et al. Validity, reliability and responsiveness of the
Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis.
Rheumatology (Oxford) 2010;49:812–19.
24 Maksymowych WP, Wichuk S, Chiowchanwisawakit P, et al. Development and
preliminary validation of the spondyloarthritis research consortium of Canada
magnetic resonance imaging sacroiliac joint structural score. J Rheumatol
2015;42:79–86.
25 Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score
(ASDAS): deﬁning cut-off values for disease activity states and improvement scores.
Ann Rheum Dis 2011;70:47–53.
26 Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind,
placebo-controlled trial of etanercept treatment in patients with active ankylosing
spondylitis. Arthritis Rheum 2003;48:1667–75.
27 Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efﬁcacy and safety of
etanercept versus sulfasalazine in patients with ankylosing spondylitis:
a randomized, double-blind trial. Arthritis Rheum 2011;63:1543–51.
28 Davis JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis
factor receptor (etanercept) for treating ankylosing spondylitis: a randomized,
controlled trial. Arthritis Rheum 2003;48:3230–6.
29 Davis JC, van der Heijde DM, Braun J, et al. Efﬁcacy and safety of up to 192 weeks
of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis
2008;67:346–52.
Maksymowych WP, et al. Ann Rheum Dis 2016;75:1328–1335. doi:10.1136/annrheumdis-2015-207596 1335
Clinical and epidemiological research
group.bmj.com on January 10, 2017 - Published by http://ard.bmj.com/Downloaded from 
EMBARK study
spondyloarthritis: 48-week results from the
early non-radiographic axial 
Clinical and MRI responses to etanercept in
Bukowski
Bonin, Ron Pedersen, Bonnie Vlahos, Sameer Kotak and Jack F 
Isabelle Logeart, Joseph Wajdula, Heather Jones, Lisa Marshall, Randi
Joachim Sieper, Jürgen Braun, Gustavo Citera, Filip Van den Bosch, 
Walter P Maksymowych, Maxime Dougados, Désirée van der Heijde,
doi: 10.1136/annrheumdis-2015-207596
12, 2015
2016 75: 1328-1335 originally published online AugustAnn Rheum Dis 
 http://ard.bmj.com/content/75/7/1328






Supplementary material can be found at: 
References
 #BIBLhttp://ard.bmj.com/content/75/7/1328
This article cites 28 articles, 12 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (1251)Inflammation
 (5144)Immunology (including allergy)
 (579)Open access
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 10, 2017 - Published by http://ard.bmj.com/Downloaded from 
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 10, 2017 - Published by http://ard.bmj.com/Downloaded from 
